FINHUB Insights

BDX · Q3 FY26 · Apr 1 – Jun 30, 2026

Becton Dickinson Q3 FY26: where the revenue came from and where it went

Becton Dickinson Q3 FY26: revenue $5.0B (+5% year over year). Net profit $0.38B. Largest cohort Medical essentials $1.6B. The whole income statement as a sankey diagram from the SEC filing.

Period
Apr 1 – Jun 30, 2026
Reported
May 7, 2026 10-Q
Sankey diagram of Becton Dickinson's income statement for Q3 FY26: revenue of $4.98 billion splits into segments and flows out into costs, taxes and net profit.
100% free

It's free. All of it.

Create a free account and every diagram unlocks. All we ask for is your email.

Continue with Google Create a free account

Already have an account? Sign in

Revenue$4.98B +5% year over year
Gross profit$2.32B 46% margin
Operating profit$0.66B 13% margin
Net profit$0.38B 8% margin

The numbers

All figures in billions of U.S. dollars, for Q3 FY26 (period ends Jun 30, 2026).
ItemValueShare of revenueYear over year
Revenue 4.98 100% +5%
Medical essentials 1.65 33%
Interventional 1.36 27%
Connected care 1.12 22%
BioPharma systems 0.59 12%
Other 0.27 5%
Cost of revenue−2.6754%
Gross profit2.3246% margin−1pp
R&D−0.265%+0pp
SG&A−1.2625%+1pp
Other−0.133%+0pp
Operating profit0.6613% margin−2pp
Tax−0.10
Interest & other costs−0.18
Net profit0.388%−5pp
Filing on EDGAR More quarters of BDX

Source of the numbers: tables in the filing (10-Q). The diagram is generated automatically and checked against EDGAR before release. How we calculate it → About and methodology.